UB Paderborn / Katalog / Suche / in CDI

Defining and treating high-grade B-cell lymphoma, NOS

Blood, 2022-09, Vol.140 (9), p.943-954

2022

Link zum Volltext

Verfügbarkeit prüfen

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

Blood, 2009-05, Vol.113 (20), p.4834-4840

2009

Link zum Volltext

Verfügbarkeit prüfen

Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities

Blood, 2015-04, Vol.125 (16), p.2471-2476

2015

Link zum Volltext

Verfügbarkeit prüfen

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

Blood, 2012-01, Vol.119 (3), p.692-695

2012

Link zum Volltext

Verfügbarkeit prüfen

The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma

Blood, 2011-07, Vol.118 (4), p.1052-1061

2011

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Blood, 2021-03, Vol.137 (10), p.1318-1326

2021

Link zum Volltext

Verfügbarkeit prüfen

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

Blood, 2014-11, Vol.124 (23), p.3356-3364

2014

Link zum Volltext

Verfügbarkeit prüfen

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma

Blood, 2019-10, Vol.134 (15), p.1238-1246

2019

Link zum Volltext

Verfügbarkeit prüfen

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study

Blood, 2019-04, Vol.133 (16), p.1762-1765

2019

Link zum Volltext

Verfügbarkeit prüfen

Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells

Blood, 2005-02, Vol.105 (3), p.1265-1273

2005

Link zum Volltext

Verfügbarkeit prüfen

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event

Blood, 2014-05, Vol.123 (18), p.2895-2897

2014

Link zum Volltext

Verfügbarkeit prüfen

T-cell non-Hodgkin lymphoma

Blood, 2006-02, Vol.107 (4), p.1255-1264

2006

Link zum Volltext

Verfügbarkeit prüfen

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Blood, 2014-10, Vol.124 (15), p.2354-2361

2014

Link zum Volltext

Verfügbarkeit prüfen

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Blood, 2021-01, Vol.137 (3), p.374-386

2021

Link zum Volltext

Verfügbarkeit prüfen

Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL)

Blood, 2020-11, Vol.136 (Supplement 1), p.6-7

2020

Link zum Volltext

Verfügbarkeit prüfen

Transcriptomic and Metabolomic Profiling Identifies Calcium-Dependent Signaling Mechanisms As a Novel and Exploitable Target to Overcome Anti-CD20 Resistance in Non-Hodgkin Lymphoma (NHL)

Blood, 2019-11, Vol.134 (Supplement_1), p.1511-1511

2019

Link zum Volltext

Verfügbarkeit prüfen

Ultra-Sensitive Detection of Circulating Serum microRNAs (miRNAs) in Diffuse Large B-Cell Lymphoma (DLBCL) Patient-Derived Xenograft (PDX) Models and Correlation with Disease Status in DLBCL Patient

Blood, 2018-11, Vol.132 (Supplement 1), p.2973-2973

2018

Link zum Volltext

Verfügbarkeit prüfen

Buparlisib/BKM120 PI3 Kinase Therapy in B Cell and T Cell Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL): Identification of Resistance Pathways and Biomarker Discovery

Blood, 2016-12, Vol.128 (22), p.2920-2920

2016

Link zum Volltext

Verfügbarkeit prüfen

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma

Blood, 2021-11, Vol.138 (Supplement 1), p.2467-2467

2021

Link zum Volltext

Verfügbarkeit prüfen

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens

Blood, 2021-11, Vol.138 (Supplement 1), p.1390-1390

2021

Link zum Volltext

Verfügbarkeit prüfen

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)-a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age

Blood, 2021-11, Vol.138 (Supplement 1), p.1966-1966

2021

Link zum Volltext

Verfügbarkeit prüfen

Systems Biology Analyses to Delineate Mechanisms of Anti-CD20 Antibody Resistance in Non-Hodgkin Lymphoma (NHL): Influence of BCR Signaling and the Critical Importance of Calcium Polarization

Blood, 2018-11, Vol.132 (Supplement 1), p.1665-1665

2018

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Defining and treating high-grade B-cell lymphoma, NOS

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study

Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells

Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event

T-cell non-Hodgkin lymphoma

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL)

Transcriptomic and Metabolomic Profiling Identifies Calcium-Dependent Signaling Mechanisms As a Novel and Exploitable Target to Overcome Anti-CD20 Resistance in Non-Hodgkin Lymphoma (NHL)

Ultra-Sensitive Detection of Circulating Serum microRNAs (miRNAs) in Diffuse Large B-Cell Lymphoma (DLBCL) Patient-Derived Xenograft (PDX) Models and Correlation with Disease Status in DLBCL Patient

Buparlisib/BKM120 PI3 Kinase Therapy in B Cell and T Cell Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL): Identification of Resistance Pathways and Biomarker Discovery

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)-a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age

Systems Biology Analyses to Delineate Mechanisms of Anti-CD20 Antibody Resistance in Non-Hodgkin Lymphoma (NHL): Influence of BCR Signaling and the Critical Importance of Calcium Polarization

Aktive Filter

Suchergebnisse filtern